← Back to patent-cliff list
Dexamethasone ophthalmic (Oculis Pharma)
Tier C — Watch / tradeDexamethasone ophthalmic (Oculis Pharma)
Oculis Pharma
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：GR
Indications (approved)：Diabetic macular oedema, 黄斑水肿, Keratitis, Postoperative pain
Regional status
US
Phase III
2021-10-19
EU
No progress
2017-09-18
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Dexamethasone ophthalmic (Oculis Pharma)?
Approved indications include: Diabetic macular oedema, 黄斑水肿, Keratitis, Postoperative pain.
When does the Dexamethasone ophthalmic (Oculis Pharma) patent expire?
No public expiry year is available for Dexamethasone ophthalmic (Oculis Pharma) yet; this page updates once verified.
How do I get a quote for Dexamethasone ophthalmic (Oculis Pharma) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21